Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2000

View Archived Issues

Ilex Oncology reports significant Q3 events

Copernicus reaches milestone in gene delivery approach to CF

Inspire reports progress in third quarter

Small-molecule Bcl-2 inhibitors sought by Structural Bioinformatics under SBIR grant

Company Profile: Angiogene

Astelin Nasal Spray approved in U.S. for treatment of nonallergic vasomotor rhinitis

MBI-594AN advances to phase II for treatment of acne

Forest to market Recordati's lercanidipine in U.S.

Investigational drug for ED discovered by Fujisawa now licensed to TAP

FDA to fast-track review of ISIS-3521 for NSCLC

IMC-C225/irinotecan shows promise for colorectal cancer in phase II trial

Gene discovery collaboration announced by Rosetta and Gemini

Neurocrine Biosciences to begin U.S. trials with altered peptide ligand for type 1 diabetes

New PARP inhibitors potentiate antitumor activity of DNA-damaging agents

Spisulosine, a marine natural product with selective activity against solid tumors

NCI-EORTC-AACR news: orally active dual topo I and II inhibitor profiled by Xenova

Second-generation tubulin-binding antitumor agent T-900607: design and characterization

Major breakthrough in HBV therapy reported at AASLD

Data presented at Heat Shock Proteins symposium support clinical application of HspE7

Significant reduction in HBV DNA obtained on adefovir dipivoxil in lamivudine-resistant HBV patients

In vivo interactions between coronary vasodilators S-nitrosocaptopril and nitroglycerin

Akzo Nobel claims new series of orally active androgens

Selective ERbeta receptor agonists synthesized by Akzo Nobel

Two series of CRF antagonists and their use in depression, anxiety, etc., presented by DuPont

Novel peptides for HCV infection emerge from R&D at Boehringer Ingelheim

Glycopeptide antibiotics discovered under joint Incara/Princeton research program

Inhibitors of cell cycle kinases and their use as anticancer agents disclosed in recent patent

Novel water-soluble trioxanes prepared at Johns Hopkins for malaria Rx

French investigators patent LTA4 hydrolase inhibitor series

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...